Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Reported Saturday, Rhythm Pharmaceuticals Reports Statistically Significant BMI Reductions In Children And Adults Across Multiple Doses And Subgroups In TRANSCEND And SIGNAL Trials

Author: Benzinga Newsdesk | July 14, 2025 02:51am
  • Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity –
  • - Full data from Phase 3 TRANSCEND study underscore potential efficacy of setmelanotide, including with prior use or concomitant use of GLP

Posted In: RYTM

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist